ADC Therapeutics SA
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ADCT | PYXS | ADAG | MGNX | HBP.TO | APLM | |
|---|---|---|---|---|---|---|
| Market cap | 219.59M | 198.30M | 161.82M | 147.15M | 70.27M | 55.38M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.2 | -1.5 | -4.3 | -1.6 | -8.4 | -29.2 |
| Price/book | -1.0 | 9.2 | 1.8 | 3.4 | 4.8 | -12.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −58.65% | −58.06% | +49.69% | +61.81% | −54.68% | +71.38% |
| Today | +10.97% | +1.22% | +2.55% | −0.86% | 0.00% | −8.83% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All ADCT news ›ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Data at ASH and Strategic Financial Restructuring Transcript
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Data at ASH and Strategic Financial Restructuring November 4, 2026 4:15 PM EST Nicole Riley - Head of Investor Relations & Corporate CommunicationsAmeet Mallik - CEO & DirectorMohamed Zaki -…
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program
Nov 04, 2026, 09:00 ET ZYNLONTA data to be featured across 5 oral presentations and multiple posters Phase 1b LOTIS-7 abstract data demonstrates an 88.7% ORR and 75.3% CR with ZYNLONTA plus glofitamab across the 97 efficacy-evaluable r/r…
ADC Therapeutics Announces New Employee Inducement Grant
/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced... LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA…
ADC Therapeutics to Present at November Investor Conferences
Nov 03, 2026, 07:15 ET LAUSANNE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two…
ADC Therapeutics: Bain Capital reports 9.99% stake
Palantir Reports Q3 2026 U.S. Comm Revenue Growth of 148% Y/Y and Revenue Growth of 96% Y/Y; Raises FY 2026 Revenue Guidance to 91% Y/Y Growth and U.S. Comm Revenue Guidance to 143% Y/Y, Crushing Consensus Expectations uniQure Announces…
ADC Therapeutics Awards 17,000 Stock Options to New Hire Under Inducement Plan
Can P&G (NYSE:PG) Stay Steady Through the Holidays? Is Coca-Cola (NYSE:KO) a Safe Haven as Rates Bite? Is PepsiCo (NASDAQ:PEP) Still a Staples Standout? Is Nike (NYSE:NKE) Ready to Sprint Again? On November 2, 2026, ADC Therapeutics SA…
NewAmsterdam Pharma (NASDAQ:NAMS) vs. ADC Therapeutics (NYSE:ADCT) Financial Analysis
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) and ADC Therapeutics (NYSE:ADCT – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their…
ADC Therapeutics Announces $86.6 Million PIPE and Loan Restructuring
ADC Therapeutics (ADCT) announced a strategic financial restructuring that includes an $86.6 million private investment in public equity financing, amendments to its HealthCare Royalty agreement, and refinancing of its senior secured…
ADC Therapeutics Raises $86.6 Million And Restructures Debt To Extend Cash Runway Into 2029
ADC Therapeutics announced a comprehensive financial restructuring that includes an $86.6 million private placement, amendments to its HealthCare Royalty agreement, and a refinancing of its senior secured loan. The company said the…
ADC Therapeutics SA (NYSE:ADCT) Stock Has Consensus Target Price of $5.00 According to Brokerages
Posted by Mitch Edgeman on Oct 10th, 2026 Check Out Our Latest Research Report on ADCT ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for the treatment…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- prnewswire.com3
- stocktitan.net3
- seekingalpha.com2
- defenseworld.net1
- european-biotechnology.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.